Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients suffering from under-addressed neurological, endocrine, psychiatric, and immunological disorders. Founded in 1992, the company's mission is to relieve suffering for individuals with significant unmet medical needs through scientific excellence and patient-centric drug development. Its corporate headquarters are located in San Diego, California.

The company's diverse portfolio includes several FDA-approved medicines. Key products include INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia (CAH). Additionally, through a collaboration with AbbVie, Neurocrine Biosciences receives royalties from products like ORILISSA (elagolix) for endometriosis and ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules) for uterine fibroids. The company recently expanded its portfolio with the acquisition of VYKAT XR for Prader-Willi Syndrome.

Recent notable developments include the acquisition of Soleno Therapeutics for approximately $2.8 billion, which added VYKAT XR to its commercial offerings, further strengthening its endocrinology and rare disease pipeline. Neurocrine Biosciences also presented new two-year data for CRENESSITY in classic congenital adrenal hyperplasia, demonstrating durable hormone control and reduced glucocorticoid exposure in both pediatric and adult patients. Kyle W. Gano, Ph.D., serves as the President and Chief Executive Officer, having been appointed in October 2024. The company maintains a robust pipeline of drug candidates in various stages of clinical development, focusing on expanding indications for existing drugs and pioneering new treatments across its therapeutic areas.

Latest updates

Neurocrine Data Bolsters CRENESSITY's Long-Term CAH Treatment Potential

Event summary

  • Neurocrine Biosciences presented two-year data from the CAHtalyst Pediatric study, involving 86 patients aged 4-17.
  • The data showed 60% of overweight/obese patients saw BMI improvements, and 61% with insulin resistance no longer exhibited it.
  • CRENESSITY enabled lower glucocorticoid (GC) dosing while maintaining hormone control, with reductions in ACTH and 17-OHP.
  • The study demonstrated improvements in androgen-related outcomes like acne and androstenedione-to-testosterone ratio.

The big picture

Neurocrine's CRENESSITY represents a significant advancement in treating classic congenital adrenal hyperplasia, a rare but debilitating condition. The two-year data reinforces the drug's ability to reduce reliance on traditional, high-dose glucocorticoids, which are associated with substantial long-term health risks. This positions Neurocrine to capture a substantial portion of the niche CAH treatment market, but sustained success will depend on demonstrating long-term efficacy and managing potential competitive pressures.

What we're watching

Adoption Rate
The long-term success of CRENESSITY hinges on physician and patient adoption, which will be influenced by reimbursement and awareness campaigns.
Competitive Landscape
While CRENESSITY currently holds a unique position, the emergence of alternative therapies for CAH could erode its market share.
Clinical Expansion
Neurocrine’s plans to share additional two-year data across clinical endpoints will be critical in establishing CRENESSITY’s long-term value proposition and potential for broader application.

Neurocrine Validates Patient-Reported Outcome Scale for Tardive Dyskinesia Treatment

Event summary

  • Neurocrine Biosciences published research in The Journal of Clinical Psychiatry defining a clinically meaningful improvement threshold of four points on the Tardive Dyskinesia Impact Scale (TDIS).
  • The TDIS, developed in partnership with neurology and psychiatry thought leaders, is the first psychometrically validated patient-reported outcome measure for tardive dyskinesia (TD).
  • The publication supports previously reported results from the KINECT-PRO™ Phase 4 study, demonstrating patient-reported improvements with INGREZZA® (valbenazine) across physical, social, and emotional functioning.
  • The KINECT-PRO™ study involved 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs.

The big picture

Neurocrine's validation of the TDIS represents a shift towards patient-centric drug development in the treatment of TD, a condition affecting an estimated 800,000 adults in the U.S. This focus on patient-reported outcomes is increasingly important for demonstrating the real-world value of therapies and securing favorable reimbursement. The TDIS's unique validation and adoption could create a barrier to entry for competitors seeking to address this underserved market.

What we're watching

Adoption Rate
The extent to which clinicians and researchers adopt the TDIS as a standard measure for assessing TD treatment response will influence Neurocrine's ability to demonstrate value and potentially impact reimbursement decisions.
Competitive Landscape
Competitors may attempt to develop alternative patient-reported outcome measures, potentially challenging the TDIS's established position and Neurocrine's market advantage.
Clinical Utility
Further research is needed to determine how the TDIS can be best integrated into clinical practice to optimize patient care and inform treatment decisions beyond the KINECT program.
CID: 731